Stay updated with breaking news from Conditionally Active Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data...
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developm...
Award recognizes Dr. Short’s contribution to science innovationSAN DIEGO, Oct. 12, 2023 -- BioAtla, Inc. , a global clinical-stage biotechnology company focused on the development of...
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the...